Skip to content
Find a Provider
Rafi R. Kazi, M.D.

Rafi R. Kazi, M.D.

Pediatrics

No ratings currently available, see text in Ratings section below for explanation.

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 275-2981

About Me

Certified Specialties

Pediatric Hematology-Oncology - American Board of Pediatrics

Pediatrics - American Board of Pediatrics

Faculty Appointments

Assistant Professor - Department of Pediatrics, Hematology and Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Pediatric Hematology-Oncology, Emory University Hospital. 2017 - 2020

Residency, Pediatrics, Strong Memorial Hospital/University of Rochester. 2015 - 2017

Internship, Pediatrics, Strong Memorial Hospital/University of Rochester. 2014 - 2015

Education

MD | University of Arkansas College of Medicine. 2014

Research

Clinical Trials

A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

Lead Researcher: Rafi R Kazi

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatmen...

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly

Lead Researcher: Rafi R Kazi

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phe...

Renal Tumors Classification, Biology, and Banking Study

Lead Researcher: Rafi R Kazi

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucl...

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Lead Researcher: Rafi R Kazi

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Umbrella Long-Term Follow-Up Protocol

Lead Researcher: Rafi R Kazi

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children'...

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.